Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 9, 2020
Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG
Jad Othman, Matthew Greenwood, John Moore, et al.
Blood
|
May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood
|
December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AML
Jad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Blood Advances
|
September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Advances
|
December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
Carlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Blood
|
August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood Cancer Discovery
|
July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States
Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Leukemia
|
August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Jad Othman, Nicola Potter, Katya Mokretar, et al.
Blood Neoplasia
|
June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
American Journal of Hematology
|
November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients
Matteo Molica, Gema Miralles, Richard Dillon, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 9, 2020
Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG
Jad Othman, Matthew Greenwood, John Moore, et al.
Blood
|
May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood
|
December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AML
Jad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Blood Advances
|
September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Advances
|
December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
Carlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Blood
|
August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood Cancer Discovery
|
July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States
Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Leukemia
|
August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Jad Othman, Nicola Potter, Katya Mokretar, et al.
Blood Neoplasia
|
June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
American Journal of Hematology
|
November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients
Matteo Molica, Gema Miralles, Richard Dillon, et al.
Page
of 5